Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma

Belyaev A.Yu.; Kobyakov G.L.; Shmakov P.N.; Telysheva E.N.; Strunina Yu.V.; Usachev D.Yu.

doi:https://doi.org/10.17116/neiro20228605121

Belyaev A.Yu.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

SPIN RSCI: 6138-9206
Scopus AuthorID: 56013296300
ORCID: 0000-0002-7651-4214

Shmakov P.N.

Burdenko Neurosurgical Center

Telysheva E.N.

Burdenko Neurosurgical Center

ORCID: 0000-0002-0370-8667

Strunina Yu.V.

Burdenko Neurosurgical Center

ORCID: 0000-0003-1696-4050

Usachev D.Yu.

Burdenko Neurosurgical Center

ORCID: 0000-0002-9811-9442

Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma

Authors:

Belyaev A.Yu., Kobyakov G.L., Shmakov P.N., Telysheva E.N., Strunina Yu.V., Usachev D.Yu.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(5): 21‑27

DOI: 10.17116/neiro20228605121

Read: 2607 times

To cite this article:

Belyaev AYu, Kobyakov GL, Shmakov PN, Telysheva EN, Strunina YuV, Usachev DYu. Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma. Burdenko's Journal of Neurosurgery. 2022;86(5):21‑27. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20228605121

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the effect of TERT mutation on overall and relapse-free survival in patients with IDH-negative diffuse astrocytomas grade III (anaplastic gliomas).

MATERIAL AND METHODS

The study included 45 patients aged 45.5 years. Forty-two patients underwent resection of tumor, other 3 ones — stereotactic biopsy. TERT mutation was identified in 21 patients. External beam radiation therapy was performed in 35 patients (60 Gy), chemotherapy — in 34 patients (mainly temozolomide). Follow-up data were available in 44 patients.

RESULTS

Median of overall survival in patients with TERT mutation was 15.3 months, in patients with TERT-negative tumors — 65.1 months. Median of relapse-free survival in patients with TERT-positive anaplastic astrocytoma (AA) was 13.3 months, in patients with TERT-negative glioma — 57.7 months. These differences were not significant. Relapse-free survival was higher in patients with AA and no TERT mutation at all intervals, but especially at early stages (12 and 24 months).

CONCLUSION

Inclusion of TERT mutation in mandatory examination panel for gliomas in general and, in particular, gliomas grade II/III without IDH mutation can lead to sub-classification of these tumors in the near future. Routine analysis of TERT mutation in these patients will be valuable for correct medical consultation regarding prognosis and adequate adjuvant treatment.

Keywords:

anaplastic astrocytoma

IDH mutation

TERT mutation

overall and disease-free survival

Authors:

Belyaev A.Yu.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

SPIN RSCI: 6138-9206
Scopus AuthorID: 56013296300
ORCID: 0000-0002-7651-4214

Shmakov P.N.

Burdenko Neurosurgical Center

Telysheva E.N.

Burdenko Neurosurgical Center

ORCID: 0000-0002-0370-8667

Strunina Yu.V.

Burdenko Neurosurgical Center

ORCID: 0000-0003-1696-4050

Usachev D.Yu.

Burdenko Neurosurgical Center

ORCID: 0000-0002-9811-9442

Received:

13.06.2022

Accepted:

19.08.2022

Close metadata

References:

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106
Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. Journal of Clinical Pathology. 2019;72(4):281-284. https://doi.org/10.1136/jclinpath-2018-205653
Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica. 2013;126(6): 907-915. https://doi.org/10.1007/s00401-013-1195-5
Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica. 2013;126(2):267-276. https://doi.org/10.1007/s00401-013-1141-6
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences. 2013;110(15):6021-6026. https://doi.org/10.1073/pnas.1303607110
Körber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, Fletcher MNC, Jones D, Hentschel B, Lamszus K, Tonn JC, Schackert G, Sabel M, Felsberg J, Zacher A, Kaulich K, Hübschmann D, Herold-Mende C, von Deimling A, Weller M, Radlwimmer B, Schlesner M, Reifenberger G, Höfer T, Lichter P. Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell. 2019;35(4):692-704.e12. https://doi.org/10.1016/j.ccell.2019.02.007
Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications. 2016;4(1):79. https://doi.org/10.1186/s40478-016-0351-2
Kikuchi Z, Shibahara I, Yamaki T, Yoshioka E, Shofuda T, Ohe R, Matsuda KI, Saito R, Kanamori M, Kanemura Y, Kumabe T, Tominaga T, Sonoda Y. TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neuro-Oncology Advances. 2020;2(1):vdaa114. https://doi.org/10.1093/noajnl/vdaa114
Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica. 2013;126(6):931-937. https://doi.org/10.1007/s00401-013-1163-0
Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology. 2017;19(3):394-404. https://doi.org/10.1093/neuonc/now189
Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. British Journal of Cancer. 2014;111(10):2024-2032. https://doi.org/10.1038/bjc.2014.538
Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica. 2017;133(6):1001-1016. https://doi.org/10.1007/s00401-017-1690-1
Arita H, Ichimura K. Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. In: Brain Tumor Pathology. Springer; 2022. https://doi.org/10.1007/s10014-021-00424-z
Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathologica Communications. 2020;8(1):201. https://doi.org/10.1186/s40478-020-01078-2
Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathologica. 2021;142(2):323-338. https://doi.org/10.1007/s00401-021-02337-9
Tesileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM, van Duinen SG, Smits M, Taphoorn MJB, French PJ, van den Bent MJ. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: A confirmation of the cIMPACT-NOW criteria. Neuro-Oncology. 2020;22(4):515-523. https://doi.org/10.1093/neuonc/noz200
Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology. 2017;19(10):1327-1337. https://doi.org/10.1093/neuonc/nox078
Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T, Goldstein M, Kim AH, Huang J. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances. 2020;2(1):vdaa126. https://doi.org/10.1093/noajnl/vdaa126
Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister SM, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica. 2015;130(3):407-417. https://doi.org/10.1007/s00401-015-1454-8
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. The survival outcomes of molecular glioblastoma IDH-wildtype: A multicenter study. Journal of Neuro-Oncology. 2022;157(1):177-185. https://doi.org/10.1007/s11060-022-03960-6